{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cough-acute-with-chest-signs-in-children/prescribing-information/short-acting-beta-2-agonists/","result":{"pageContext":{"chapter":{"id":"f40afbec-15db-5ba5-8bf8-b4ddeee5aeec","slug":"short-acting-beta-2-agonists","fullItemName":"Short-acting beta-2 agonists","depth":2,"htmlHeader":"<!-- begin field a323594f-4e3f-493c-b2ec-a70100f66d5d --><h2>Short-acting beta-2 agonists</h2><!-- end field a323594f-4e3f-493c-b2ec-a70100f66d5d -->","summary":"","htmlStringContent":"<!-- begin item c1f2461f-504c-45da-a51e-a70100f66a31 --><!-- end item c1f2461f-504c-45da-a51e-a70100f66a31 -->","topic":{"id":"ecc57759-d8a2-50b5-addc-68127dd57e13","topicId":"6f239a86-8a9f-4fc1-85b2-df045fbf9477","topicName":"Cough - acute with chest signs in children","slug":"cough-acute-with-chest-signs-in-children","lastRevised":"Last revised in January 2021","chapters":[{"id":"82620eeb-35c8-583d-957c-c8c9d68f0bc4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"85e154c6-7444-55c1-8105-4238c565d6d6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"34d842b6-5846-5142-96f5-6451b7b9503f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94ebcc3a-8e44-5c7a-84a1-44c122e86fc5","slug":"changes","fullItemName":"Changes"},{"id":"19991281-8b30-5f16-8552-ba71a6c2257f","slug":"update","fullItemName":"Update"}]},{"id":"31245ad9-f63e-5053-8f0f-9e310f133212","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1846e94-64be-5a1d-b26e-9bc518192b43","slug":"goals","fullItemName":"Goals"},{"id":"52d51fe3-1e3c-5479-82e5-628353de2bda","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"59199121-d653-59c9-a7ff-03835d711500","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73cf3120-d25a-5284-8593-e93c81d39c8d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4f7d288f-bf0c-5dd9-aad8-54ef82e7e039","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"60fdd9e2-e6fd-5e5b-98d4-33afb2271bf6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"40cbe9e5-667a-56f8-9039-e094f48e40da","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b9756443-edc1-5707-af00-970491b93f52","slug":"definition","fullItemName":"Definition"},{"id":"ef20d952-44e6-5372-8021-cb07f3444dc1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"39f5f767-cf1c-554f-ac8c-1c89c7b73a53","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"eee4bb33-4743-5ff3-b4e0-221f6f6670c7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"476813be-e2a1-5849-b379-e674dda72f03","slug":"diagnosis-of-cause","fullItemName":"Diagnosis of cause"},{"id":"b9d5f16f-3395-562d-a46b-b1f06bd6bed5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"899fa269-48ce-5ff0-82b9-83b8bbd23fd5","fullItemName":"Management","slug":"management","subChapters":[{"id":"a34c98a9-afaf-51ce-9449-23569af98723","slug":"viral-induced-wheeze-possible-asthma","fullItemName":"Scenario: Viral-induced wheeze/possible asthma"},{"id":"87edfa6f-d156-5750-9778-a82799c16245","slug":"bronchiolitis","fullItemName":"Scenario: Bronchiolitis"},{"id":"aa61e13e-692a-56aa-a17b-a9429aa076d0","slug":"community-acquired-pneumonia","fullItemName":"Scenario: Community-acquired pneumonia"}]},{"id":"e3645b31-0302-5b3c-ad3d-fad31e7f02f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f1a05b5b-c5fe-5138-a544-4d447c78a07e","slug":"amoxicillin-co-amoxiclav","fullItemName":"Amoxicillin and co-amoxiclav"},{"id":"82dc91ea-2a15-5ea8-979f-6ff8f0d34a7a","slug":"cefaclor","fullItemName":"Cefaclor"},{"id":"64d06ec1-7d56-574c-a9cc-ee35cfd204e4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"20c13e81-9ef3-5df6-9f51-eb0dfacaaeab","slug":"ibuprofen-paracetamol","fullItemName":"Ibuprofen and paracetamol"},{"id":"87a5f8d7-3f8e-5b8e-81b4-364a14a73467","slug":"macrolides","fullItemName":"Macrolides"},{"id":"0697a2ca-e9c2-512d-ab11-d573f39abddf","slug":"prednisolone","fullItemName":"Prednisolone"},{"id":"f40afbec-15db-5ba5-8bf8-b4ddeee5aeec","slug":"short-acting-beta-2-agonists","fullItemName":"Short-acting beta-2 agonists"}]},{"id":"91f18501-a585-5063-808d-45ce72bc128b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87a7a774-5455-587b-b324-53fd94fb5173","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0ddbcc1e-d9b8-5a7f-becd-f71b188dbbd0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d35bce52-adec-5cb7-9ea1-acf95169edd6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a68992e4-ba15-5c95-9370-e987b9a61f0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"610e5926-a430-5217-a4dc-6de7f4a3d7c8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d9335bd0-caf6-5162-a6c3-4efb35bf6011","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b3e96fe7-7269-59f4-8328-c9710f4dbc76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e3645b31-0302-5b3c-ad3d-fad31e7f02f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"cc775b25-e6f0-5304-b86f-ca2fc276618f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 727cb929-8337-423b-bac2-a70100f95a51 --><h3>Contraindications and cautions</h3><!-- end field 727cb929-8337-423b-bac2-a70100f95a51 -->","summary":"","htmlStringContent":"<!-- begin item 2c6d2626-fd85-4688-b4e3-a70100f9558b --><!-- begin field 12f57049-bf94-47c9-a30a-a70100f95a51 --><ul><li><strong>Beta-<sub>2</sub> agonists should be used with caution in people with:</strong><ul><li>Hyperthyroidism — beta-<sub>2</sub> agonists may stimulate thyroid activity.</li><li>Diabetes mellitus — there is a rare risk of ketoacidosis (especially after intravenous beta-<sub>2 </sub>agonist administration). Additional blood glucose measurements are recommended when treatment with a beta-<sub>2</sub> agonist is commenced.</li><li>Cardiovascular disease (including hypertension) — beta-<sub>2</sub> agonists may cause an increased risk of arrhythmias and significant changes to blood pressure and heart rate.</li><li>Susceptibility to QT-interval prolongation.</li><li>Hypokalaemia — plasma potassium concentration may be reduced by beta-<sub>2</sub> agonists (particularly high doses).</li><li>Convulsive disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>]</p><!-- end field 12f57049-bf94-47c9-a30a-a70100f95a51 --><!-- end item 2c6d2626-fd85-4688-b4e3-a70100f9558b -->","subChapters":[]},{"id":"976d5eca-4da7-5538-aeae-b8b5e6a10b75","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1dcb434c-07fb-4fee-b4ef-a70100f98d46 --><h3>Adverse effects</h3><!-- end field 1dcb434c-07fb-4fee-b4ef-a70100f98d46 -->","summary":"","htmlStringContent":"<!-- begin item af02030a-9082-4008-baed-a70100f98742 --><!-- begin field dab8551f-2ac6-4e3e-b7e0-a70100f98d46 --><ul><li><strong>Adverse effects of short-acting beta-<sub>2</sub> agonists are usually dose related and include:</strong><ul><li>Fine tremor — occurs particularly in the hands and is usually worse in the first few days of treatment.</li><li>Palpitations.</li><li>Headache.</li><li>Seizure.</li><li>Anxiety.</li><li>Hypokalaemia.</li><li>Cardiac arrhythmia and paradoxical bronchospasm (rare).</li></ul></li><li>Advise people who are using terbutaline turbohaler to rinse their mouth with water after each use. A fraction of the dose will always be deposited in the mouth and rinsing will minimize the amount of drug that is absorbed systemically.</li><li><strong>The risk of adverse events may be higher in people with a predisposition to arrhythmias and in people with pre-existing cardiovascular disease, or hypertension.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>]</p><!-- end field dab8551f-2ac6-4e3e-b7e0-a70100f98d46 --><!-- end item af02030a-9082-4008-baed-a70100f98742 -->","subChapters":[]},{"id":"7165cd7d-d494-566d-96f4-f76cdf496564","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a9fac43b-fcc0-432e-ab74-a70100f9b5bd --><h3>Drug interactions</h3><!-- end field a9fac43b-fcc0-432e-ab74-a70100f9b5bd -->","summary":"","htmlStringContent":"<!-- begin item 35cb3a11-883f-40e3-902e-a70100f9b031 --><!-- begin field 0e23db6b-6224-457d-b61a-a70100f9b5bd --><p><strong>Drug interactions with short-acting beta-2 agonists include:</strong></p><ul><li><strong>Corticosteroids, diuretics, and xanthine derivatives such as theophylline</strong> — monitor potassium levels.<ul><li>Beta-<sub>2 </sub>agonists can cause hypokalaemia (particularly at high doses), and this can be increased by other potassium-depleting drugs, such as corticosteroids, loop diuretics, and xanthine derivatives.</li></ul></li><li><strong>Digoxin </strong>— monitor potassium levels and be alert to signs of digoxin toxicity, such as loss of appetite, nausea, vomiting, bradycardia, visual disturbance, and drowsiness.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>]</p><!-- end field 0e23db6b-6224-457d-b61a-a70100f9b5bd --><!-- end item 35cb3a11-883f-40e3-902e-a70100f9b031 -->","subChapters":[]},{"id":"70632a3b-f08c-5fac-8887-4560997c899d","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field 8909322a-56af-44ba-b1d9-a70100f9de9f --><h3>Dosing information</h3><!-- end field 8909322a-56af-44ba-b1d9-a70100f9de9f -->","summary":"","htmlStringContent":"<!-- begin item 79b51cfb-8f5a-4328-a007-a70100f9d936 --><!-- begin field 37e3ba3a-c6cb-48b1-9701-a70100f9de9f --><ul><li><strong>Short-acting beta-<sub>2</sub> agonists (SABAs),</strong> such as salbutamol and terbutaline, have a rapid onset of action (15 minutes) and their effects last for up to 4 hours.<ul><li>Doses vary depending on the child's age, response to treatment and the preparation prescribed. For more details, see the <a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"f352600e-26c7-4aba-92d3-a98f01582cac\">British National Formulary</a> and the manufacturers' Summaries of Product Characteristics.</li><li>Use of a SABA as required is at least as effective as regular (four times daily) use. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/references/\">BTS/SIGN, 2016</a>]</p><!-- end field 37e3ba3a-c6cb-48b1-9701-a70100f9de9f --><!-- end item 79b51cfb-8f5a-4328-a007-a70100f9d936 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}